September’s top five retina articles
Recent retina/vitreous articles discuss study results and new trials. Here are five popular items from the first half of September on Healio/OSN:
Alimera enrolls first patient in Iluvien trial
Alimera Sciences has initiated enrollment for its prospective Iluvien study New Day. Read more.
LumiThera receives NEI grant in support of clinical trial
LumiThera Inc. is the recipient of a $1.5 million grant from the National Eye Institute in support of a clinical trial investigating a new treatment for diabetes-related ocular pathology. Read more.
Lineage Cell Therapeutics receives grant to fund novel bio-retinal patch
Lineage Cell Therapeutics was awarded a grant worth more than $500,000 for the development of a bio-retinal patch for the treatment of retinal diseases. Read more.
Enspryng reduces risk, severity of relapse in neuromyelitis optica spectrum disorder
Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting. Read more.
Lapse in care may yield lost visual acuity in AMD
Patients with neovascular age-related macular degeneration who have a 3 month or longer lapse of anti-VEGF treatment may experience unrecoverable loss of vision. Read more.